⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI

Official Title: A Randomized, Placebo-controlled Phase II Trial Investigating SUNITINIB Versus Placebo in Patients With Chemorefractory Advanced Adenocarcinoma of the Stomach or Lower Esophagus Treated With Chemotherapy FOLFIRI

Study ID: NCT01020630

Conditions

Adenocarcinoma

Interventions

Sunitinib
Placebo

Study Description

Brief Summary: This trial will be conducted to evaluate the efficacy, safety and tolerability of SUNITINIB as add-on therapy with a widely used second-line palliative FOLFIRI chemotherapy in patients with chemo-refractory advanced or metastatic adenocarcinoma of stomach or lower esophagus (mGC). There is a clear scientific rationale for the use of Sunitinib to treat patients with mGC. Despite recent therapeutic advances, the median overall survival (OS) in patients with mG is still ≤ 12 months. Therefore, newer agents with novel mechanisms of action are desperately needed for treatment of these patients.

Detailed Description: In parallel to the efforts in front-line therapy, second-line protocols like irinotecan-based regimens have been established in clinical trials for those patients. As many patients are still in good performance status and present with low tumor burden after failure of first-line chemotherapy, they clearly benefit from second-line treatment. Sunitinib inhibits the receptor tyrosine kinases (RTKs) involved in tumor proliferation and angiogenesis, specifically the VEGFR, PDGFR, KIT, FLT-3, and RET. The VEGF pathway has been shown to be a significant factor in metastatic gastric cancer. The safety and efficacy of Sunitinib as single agent for the treatment of mGC has been determined and support the proposed clinical study with FOLFIRI in combination with Sunitinib in the treatment of patients with mGC. Patients included in this trial suffer from advanced or metastatic adenocarcinoma of stomach or lower esophagus. They have failed to respond at least to one standard palliative first-line therapy (based on docetaxel and/or cisplatin plus 5-FU). Irinotecan/FA/5-FU can be determined as one established second-line treatment to be available for these patients. Taken together, treatment of those patients with Sunitinib combined with standard chemotherapy FOLFIRI offers the chance to benefit from a new innovative therapy with acceptable side effects.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Universitätsmedizin Mainz, 1. Med. Klinik, Mainz, Rheinland-Pfalz, Germany

Gesundheitszentrum St. Marien, Amberg, , Germany

Helios Klinikum Berlin-Buch, Berlin, , Germany

Universitätsmedizin Berlin Charite, Berlin, , Germany

Evangelisches Krankenhaus Bielefeld, Bielefeld, , Germany

Universitätsklinikum Essen, Essen, , Germany

Kliniken Essen-Mitte, Essen, , Germany

Krankenhaus Nordwest, Frankfurt, , Germany

Martin-Luther-Universität Halle-Wittenberg, Halle, , Germany

MVZ fĂźr Innere Medizin in Hamburg-Eppendorf, Hamburg, , Germany

Universitätsklinikum des Saarlandes, Homburg, , Germany

Klinikum Ludwigsburg Medizinische Klinik I, Ludwigsburg, , Germany

Technische Universität Mßnchen, Mßnchen, , Germany

Universitätsklinikum Rostock Klinik fßr Innere Medizin, Rostock, , Germany

Leopoldina-Krankenhaus der Stadt Schweinfurt gGmbH, Schweinfurt, , Germany

Klinikum Weiden, Weiden, , Germany

Contact Details

Name: Markus Moehler, MD

Affiliation: Johannes Gutenberg University Mainz, 1. Med. Klinik

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: